MedTrace Logo

Study of Artesunate in Metastatic Breast Cancer

NCT00764036 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2017-08-01

No results posted yet for this study

Summary

The purpose of this study is to evaluation the tolerability of an add-on therapy with artesunate with a duration of 4 weeks in patients with advanced breast cancer.

Conditions

Interventions

DRUG

artesunate

add-on therapy with daily single oral doses of 100, 150 or 200 mg of artesunate

Sponsors & Collaborators

  • Hector-Stiftung

    collaborator OTHER

  • Dafra Pharma

    collaborator INDUSTRY

  • Monika-Kutzner Stiftung, Berlin, Germany

    collaborator UNKNOWN

  • HEIFAN-Heidelberger Förderverein d. Ambulanz f. Naturheilkunde eV, Heidelberg, Germany

    collaborator UNKNOWN

  • Heidelberg University

    lead OTHER

Principal Investigators

  • Cornelia U v. Hagens, MD · Department of Gynecological Endocrinology and Reproductive Medicine

Study Design

Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2013-11-30
Completion
2013-11-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00764036 on ClinicalTrials.gov